SRRK vs ARQT vs REGN vs LLY

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Scholar Rock Holding Corporation (SRRK) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Eli Lilly and Company at 42. 5x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 15. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 0. 98x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to -39. 5% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: LLY returned +1238% versus ARQT's -5. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

71β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 109% more volatile than LLY relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -33. 2% for Scholar Rock Holding Corporation. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 0. 98x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 15. 3x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 62. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 71. 8% to $35. 50.

In this comparison, LLY (0.

6% yield), REGN (0. 5% yield) pay a dividend. SRRK, ARQT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Both have compounded well over 10 years (LLY: +1238%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRRK is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; LLY is a large-cap high-growth stock. LLY pays a dividend while SRRK, ARQT, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.